MATERIALS LICENSE

Amendment No. 01

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Kennedy Memorial Hospitals at Saddle Brook	In accordance with application dated May 15, 1984 3. License number 29-18240-01 is amended in its entirety to read as follows:
2. P.O. Box 561 300 Market Street Saddle Brook, New Jersey 07662	4. Expiration date October 31, 1990
	5. Docket or Reference No. 030-14715

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 6.A.
B. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	B. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	B. As necessary for uses authorized in Subitem 9.B.
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Prepackaged kits	C. 5 millicuries of each byproduct material authorized in Subitem 6.C.
D. Iodine 131	D. Any iodide that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	D. 500 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. In vitro studies.
D. For treatment of thyroid carcinoma.

ML10

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
29-18240-01

Docket or Reference number
030-14715

Amendment No. 01

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities, Kennedy Memorial Hospitals at Saddle Brook, 300 Market Street, Saddle Brook, New Jersey.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

William L. Palazzo, M.D.	Groups I, II and IV In vitro studies Iodine 131 for treatment of thyroid carcinoma
Edward Darzo, M.D.	In vitro studies

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

    (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

    The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

(16. continued) CONDITIONS

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated May 15, 1984 and letter dated October 25, 1984 which contains ALARA program, August 19, 1985, September 3, 1985 and October 8, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed By:
By John E. Glenn
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406

Date NOV 0 5 1985